VIDEO: Faricimab shows greater reduction in macular leakage vs. aflibercept in DME

ByRoger A. Goldberg, MD, MBA

ByDavid W. Mullin

Fact checked byChristine Klimanskis, ELS

Key takeaways:

A study at the ARVO meeting discussed macular leakage in the YOSEMITE and RHINE studies.
Faricimab resulted in a greater reduction in macular leakage compared with aflibercept.

NEW ORLEANS — In this Healio Video Perspective from the ARVO meeting, Roger A. Goldberg, MD, MBA, discusses results from the YOSEMITE and RHINE studies.

The trials compared aflibercept to faricimab for the treatment of diabetic macular edema.

“Faricimab did a better job at reducing macular leakage vs. aflibercept after four loading doses of both drugs,” Goldberg said.

Published by:

Sources/Disclosures

Collapse

Source:

Goldberg RA, et al. Faricimab reduces macular leakage vs aflibercept in patients with DME. Presented at: Association for Research in Vision and Ophthalmology meeting; April 23-27, 2023; New Orleans.

Disclosures: Goldberg reports being an investigator for Genentech and a consultant for Genentech and Regeneron.